Darlene Dobkowski, MA

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

Women who underwent radiation after cancer surgery had improved distant metastases-free survival rates, although this benefit was not evident in overall survival.

Onureg, an oral form of the chemotherapy azacitidine, in older patients with acute myeloid leukemia who were in remission after chemotherapy contributed to longer survival outcomes, compared to placebo.

A survey conducted by the LUNGevity Foundation determined that 96% of patients with lung cancer felt that they were concerned about the COVID-19 pandemic affecting their treatment.

In a survey conducted by the Cancer Support Community, 33% of patients with lung cancer reported they were somewhat or not at all involved in the decision-making process, and 66% were not as knowledgeable about their treatment options as needed to make this decision.

Tecentriq with carboplatin and etoposide led to a median overall survival rate of 12.3 months versus 10.3 months in those assigned placebo, carboplatin and etoposide, although the death rate was high at a median follow-up of 22.9 months.

At three years, overall survival in men with nonmetastatic, castration-resistant prostate cancer treated with Nubeqa was 83% compared with 77% in those who received placebo.

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response.

The other half of the Siegfried and Roy duo famous for their Vegas act died on Thursday from terminal pancreatic cancer.

In this episode of the “CURE Talks Cancer” podcast, we spoke with someone who has undergone 41 surgeries and physically debilitating treatments during his more than 15-year journey with several cases of skin cancer. We discussed his cancer journey, and why, as he starts a new treatment after his most prior therapy failed, he’s focused on quality rather than quantity of life.

Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.

Researchers observed the benefit of adhering to a Mediterranean diet in all men, in addition to non-White men and those without diabetes.

Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.

In participants who reported that the pandemic negatively impacted their decision to enroll in a clinical trial, some of the most common reasons included exposure to the virus and limited access to care.

In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.

The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.

The study found that the risk increased despite receiving care at a highly specialized center, although neighborhood poverty did not have the same degree of impact on children with the nonmalignant disease.

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

With the second COVID-19 vaccine receiving emergency use authorization by the FDA, patients with cancer undergoing treatment should keep in mind how it may affect their therapy and the potential difference between the two vaccines by Pfizer-BioNTech and Moderna.

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

The Moderna COVID-19 Vaccine is delivered similarly to the Pfizer-BioNTech Vaccine, with two doses a month apart. This adds a second vaccine to the arsenal for COVID-19 prevention.

This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.

Orgovyx is the first oral drug to treat patients with advanced prostate cancer, who were previously treated with intravenous drugs that required clinic visits.

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.

As treatment delays become more common – especially with the COVID-19 pandemic – delays as much as four weeks can impact the risk for mortality in seven different types of cancer.

This study also found that women with higher waist circumferences had a higher risk for cancer-related and all-cause death compared with those with lower waist circumferences.